Perspective Therapeutics (NYSE:CATX) Given Overweight Rating at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Perspective Therapeutics (NYSE:CATX) in a report released on Tuesday, Benzinga reports.

CATX has been the subject of several other research reports. Bank of America began coverage on Perspective Therapeutics in a research note on Thursday, July 25th. They set a buy rating and a $24.00 target price for the company. Lifesci Capital reiterated an outperform rating on shares of Perspective Therapeutics in a research note on Monday, May 6th. Oppenheimer decreased their price target on Perspective Therapeutics from $19.00 to $17.00 and set an outperform rating for the company in a report on Tuesday, August 13th. Finally, Royal Bank of Canada cut their price objective on shares of Perspective Therapeutics from $29.00 to $27.00 and set an outperform rating for the company in a research report on Friday, August 16th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of Buy and a consensus price target of $19.80.

Perspective Therapeutics Trading Down 10.3 %

Shares of CATX stock opened at $14.18 on Tuesday. The stock’s 50-day moving average price is $12.74. Perspective Therapeutics has a 12 month low of $2.05 and a 12 month high of $19.05.

Perspective Therapeutics (NYSE:CATX) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.04. The business had revenue of $0.53 million for the quarter. On average, research analysts anticipate that Perspective Therapeutics will post -0.87 EPS for the current fiscal year.

Insider Activity at Perspective Therapeutics

In other Perspective Therapeutics news, Director Lori A. Woods bought 4,587 shares of the company’s stock in a transaction that occurred on Friday, June 14th. The stock was purchased at an average price of $10.90 per share, with a total value of $49,998.30. Following the transaction, the director now owns 159,985 shares in the company, valued at $1,743,836.50. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, Director Lori A. Woods acquired 4,587 shares of the firm’s stock in a transaction on Friday, June 14th. The stock was bought at an average cost of $10.90 per share, with a total value of $49,998.30. Following the transaction, the director now directly owns 159,985 shares in the company, valued at approximately $1,743,836.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Johan M. Spoor purchased 10,000 shares of the business’s stock in a transaction that occurred on Thursday, June 13th. The stock was acquired at an average price of $11.70 per share, for a total transaction of $117,000.00. Following the purchase, the chief executive officer now owns 13,757 shares of the company’s stock, valued at approximately $160,956.90. The disclosure for this purchase can be found here. In the last quarter, insiders bought 16,387 shares of company stock valued at $184,656. 3.52% of the stock is owned by insiders.

Hedge Funds Weigh In On Perspective Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its position in Perspective Therapeutics by 34.6% in the 1st quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock valued at $21,158,000 after buying an additional 4,566,356 shares in the last quarter. Janus Henderson Group PLC purchased a new stake in Perspective Therapeutics in the 1st quarter worth about $15,511,000. Affinity Asset Advisors LLC acquired a new stake in shares of Perspective Therapeutics during the first quarter worth approximately $6,069,000. Ally Bridge Group NY LLC purchased a new position in shares of Perspective Therapeutics during the 2nd quarter valued at $3,951,000. Finally, WealthPLAN Partners LLC acquired a new position in Perspective Therapeutics in the 2nd quarter worth about $1,695,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.